A 222-quarter payment streak continues as Chemed declares another 70-cent dividend

Chemed Corporation (NYSE:CHE) declared a quarterly cash dividend of $0.70 per share, payable December 4, 2026. This marks the 222nd consecutive quarterly dividend. The company operates VITAS Healthcare and Roto-Rooter. Chemed noted that forward-looking statements involve risks and uncertainties.

Original reporting
Published Nov 6, 2026, 4:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CHE
Neutral
high confidence
Mentioned
$CHE
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CHENeutralLow
01

Why it matters

The dividend maintains Chemed's reputation for consistent shareholder returns, but does not materially alter valuation.

02

Market read

A routine dividend announcement with modest impact; primarily relevant to income‑oriented investors.

03

What to watch

Potential tax considerations for dividend‑focused investors and the upcoming fiscal year guidance could be more material.

Relevance 5/10Novelty 4/10Timing: after announcement today

Background

Chemed Corp operates VITAS Healthcare and Roto‑Rooter, providing hospice care and plumbing services respectively.

Company-level read

Ticker impact

$CHENeutralHigh confidence
Context

Chemed Corp announced a 70‑cent quarterly dividend, its 222nd consecutive payment.

Expected impact

likely slight upward pressure as income investors price in the dividend

Evidence & confidence

Dividends are a routine corporate action; the amount is modest and does not signal a material change in fundamentals.

Market effects

Minimal impact on the healthcare and plumbing services sectors; reinforces Chemed's stable cash flow profile.

Limited to U.S. investors focused on dividend yields.

None

Counterpoint

The dividend may mask underlying growth concerns; investors could view the modest payout as a sign of limited reinvestment opportunities.

Key entities

  • Chemed Corporation

    Provider of hospice care and plumbing services, ticker CHE.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.